The SARS-CoV-2 Spike Protein is essential in the attack on human cells and is therefore an important target in the development of therapeutics and vaccines.
In the development of most COVID-19 vaccines, the Spike Protein was used to trigger the immune response. The structural change by the replacement of two proline amino acids in the S2 subunit of the Spike Protein (S-2P), stabilizes the trimer and keeps the protein longer in prefusion state, which leads to a stronger immune response.
Recent research results indicate that four additional proline mutations in the S2 subunit (S-6P) stabilize the structure of the trimer even more and keeps most of the protein in prefusion state. That means, S-6P shows superior bioactivity over S-2P.
S-6P shows the best result when comparing the signal-to-noise ratios of four different Spike Trimer Proteins using ten different patient samples. In conclusion: S-6P is the best recombinant protein for the vaccine immunogenicity evaluation.
antibodies-online offers a series of S-6P proteins